Pharvaris: Pharvaris is focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. Pharvaris uses small molecules to advance potent, orally available compounds targeting HAE. The company was founded by the former founders of Prosensa and Jerini and reunites the core team responsible for the discovery and approval of the HAE treatment icatibant.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Other
Disease Space
Dermatology, Gastrointestinal, Rare Disease
Industry
Pharmaceuticals, Specialty Pharmaceutical
Listing
Private
Website:
Profiles:
Address:
Leiden Bio Science Park
J.H. Oortweg 21
Leiden, 2333 BD
The Netherlands